Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Entrada Therapeutics (TRDA) Return on Invested Capital (2024 - 2025)

Historic Return on Invested Capital for Entrada Therapeutics (TRDA) over the last 3 years, with Q3 2025 value amounting to 0.33%.

  • Entrada Therapeutics' Return on Invested Capital fell 4300.0% to 0.33% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.33%, marking a year-over-year decrease of 4300.0%. This contributed to the annual value of 0.14% for FY2024, which is 1300.0% up from last year.
  • According to the latest figures from Q3 2025, Entrada Therapeutics' Return on Invested Capital is 0.33%, which was down 4300.0% from 0.23% recorded in Q2 2025.
  • Over the past 5 years, Entrada Therapeutics' Return on Invested Capital peaked at 0.25% during Q2 2024, and registered a low of 0.43% during Q2 2023.
  • In the last 3 years, Entrada Therapeutics' Return on Invested Capital had a median value of 0.01% in 2023 and averaged 0.09%.
  • Its Return on Invested Capital has fluctuated over the past 5 years, first skyrocketed by 6800bps in 2024, then crashed by -4800bps in 2025.
  • Over the past 3 years, Entrada Therapeutics' Return on Invested Capital (Quarter) stood at 0.01% in 2023, then skyrocketed by 1425bps to 0.11% in 2024, then plummeted by -407bps to 0.33% in 2025.
  • Its Return on Invested Capital stands at 0.33% for Q3 2025, versus 0.23% for Q2 2025 and 0.01% for Q1 2025.